Novartis drug discovery innovation is transforming global health through the Biomedical Research group's shift from siloed efforts to an integrated, patient-centric model targeting high-burden diseases in low- and middle-income countries (LMICs). Under Manju Ujjini, Head of Lead Discovery, key mi...

Infarmed regulatory activity in January 2026 showcased robust performance by Portugal's National Authority for Medicines and Health Products, spanning marketing authorizations, clinical trials, public reimbursement, inspections, pharmacovigilance, and enforcement. The agency processed 45 renewals...

BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) an...

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per month across key doses, effective January 1, 2027....

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which recommends it for non-segmental vitiligo with...

SAHPRA GMP compliance at Adcock Ingram's Clayville facility has been reaffirmed by the South African Health Products Regulatory Authority (SAHPRA) in its